Incidence of FLT3/ITD+ patients in different cytogenetic risk groups and subgroups
| Cytogenetics . | Total . | FLT3/ITD− . | FLT3/ITD+ . | Percent FLT3/ITD+ . | P . |
|---|---|---|---|---|---|
| Favorable risk | 242 | 184 | 58 | 24 | |
| t(15;17) | 133 | 84 | 49 | 37 | .002 |
| t(8;21) | 67 | 61 | 6 | 9 | .0004 |
| inv(16) | 42 | 39 | 3 | 7 | .003 |
| Intermediate risk | 434 | 302 | 132 | 30 | |
| Normal | 281 | 185 | 96 | 34 | .0001 |
| del(7q) | 20 | 18 | 2 | 10 | .1 |
| 11q23 | 18 | 18 | 0 | 0 | .006 |
| +8 | 74 | 53 | 21 | 28 | .7 |
| +22 | 12 | 10 | 2 | 17 | .7 |
| Adverse risk | 79 | 73 | 6 | 8 | |
| Complex | 44 | 43 | 1 | 2 | .00003 |
| del(5q) | 19 | 19 | 0 | 0 | .006 |
| −5 | 16 | 16 | 0 | 0 | .02 |
| −7 | 30 | 28 | 2 | 7 | .01 |
| abn(3q) | 23 | 19 | 4 | 17 | .5 |
| Unknown | 99 | 68 | 31 |
| Cytogenetics . | Total . | FLT3/ITD− . | FLT3/ITD+ . | Percent FLT3/ITD+ . | P . |
|---|---|---|---|---|---|
| Favorable risk | 242 | 184 | 58 | 24 | |
| t(15;17) | 133 | 84 | 49 | 37 | .002 |
| t(8;21) | 67 | 61 | 6 | 9 | .0004 |
| inv(16) | 42 | 39 | 3 | 7 | .003 |
| Intermediate risk | 434 | 302 | 132 | 30 | |
| Normal | 281 | 185 | 96 | 34 | .0001 |
| del(7q) | 20 | 18 | 2 | 10 | .1 |
| 11q23 | 18 | 18 | 0 | 0 | .006 |
| +8 | 74 | 53 | 21 | 28 | .7 |
| +22 | 12 | 10 | 2 | 17 | .7 |
| Adverse risk | 79 | 73 | 6 | 8 | |
| Complex | 44 | 43 | 1 | 2 | .00003 |
| del(5q) | 19 | 19 | 0 | 0 | .006 |
| −5 | 16 | 16 | 0 | 0 | .02 |
| −7 | 30 | 28 | 2 | 7 | .01 |
| abn(3q) | 23 | 19 | 4 | 17 | .5 |
| Unknown | 99 | 68 | 31 |
P values are from Fisher exact test for each individual cytogenetic abnormality versus all other known karyotypes.